Pfizer's twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped obesity drugs. Pfizer's move to drop two obesity drug candidates in the last year ...
Pfizer shares sank Friday when the drugmaker said it would abandon a twice-daily ... obesity but without type 2 diabetes. It ranged from nearly 7% to more than 11% in patients taking the pills.
There’s no question, however, that the decision to abandon the twice-daily version introduces a significant delay to Pfizer’s plans to enter the obesity market, which has been transformed in ...
Pfizer is advancing on a broad front in its attempt to catch up with Novo Nordisk and Eli Lilly in the obesity drug category ... it had decided to drop the twice-daily version, after seeing ...
(Bloomberg) -- Obesity ... daily at the highest dose to adults with obesity, according to a mid-stage study published last year. Drugmakers including Pfizer Inc. and AstraZeneca Plc also have ...
Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...
Doubling down on the bad news, Pfizer's journey into the weight loss drug market has fallen flat, as its twice-daily obesity-fighting pill danuglipron triggered nausea and other stomach issues in ...
Yet that hasn’t been enough to appease investors who have worried that Pfizer missed the boat on booming demand for obesity ... of the year, a twice-daily version of a second pill was shelved.
The drugmaker responsible for bringing the controversial abortion pill to the U.S. is now pursuing a new use that could widen women’s access: treating miscarriages, The Wall Street Journal reports.
In the latest market close, Pfizer (PFE) reached $29.08, with a -0.27% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 0.77%. Meanwhile ...
Bourla was pivotal in developing Pfizer’s COVID-19 vaccine Comirnaty with BioNTech. During the pandemic, Pfizer gave the world the first and most widely used vaccine, Comirnaty, and the oral antiviral ...